阿雷替尼(Alecensa)

Alecensa is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) that has progressed or is resistant to crizotinib. It was approved by the U.S. FDA on December 11, 2015.

[Usage and Dosage]

600 mg (4 tablets) twice a day, taken after meals.

[Adverse Reactions]

[Storage]

Store at room temperature between 20°C and 25°C; outings are allowed between 15°C and 30°C.